Latest News for: nk cell

Edit

Bharat Biotech forays into cell and gene therapy with $75 million vertically integrated CGT, viral production facility at Genome Valley

The Times of India 20 Mar 2025
We already have a pipeline of five products that we are working on with therapies such as CAR-T cell, CAR-NK cell as well as off-the-shelf gene therapies,” Raches Ella said.“Our established expertise ...
Edit

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

ACCESSWIRE 18 Mar 2025
APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell and NK cell activation.
Edit

Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom

GetNews 18 Mar 2025
The company’s proprietary platform creates engineered iPSC lines for off-the-shelf T-cell and NK-cell products, targeting diseases in autoimmunity and oncology ... The company’s FT522 CAR NK ...
Edit

NK Cell Therapy Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, ...

GetNews 17 Mar 2025
NK Cell Therapy Report Metrics Details Study Period 2020–2034 NK Cell Therapy Report Coverage 7MM Key NK Cell Therapy Companies Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta ...
Edit

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation

GetNews 17 Mar 2025
(NasdaQ ... Exclusive License to GEARCell Therapy. A breakthrough approach in cancer treatment leveraging genetically modified natural killer (NK) cells to enhance deep remission in patients with hematologic malignancies and solid tumors ... (NYSE.
Edit

Shiitake mushrooms and canine cancer

Manila Standard 15 Mar 2025
... to mast cell tumors ... Studies suggest that lentinan may enhance the activity of natural killer (NK) cells and macrophages, which play a critical role in identifying and destroying cancerous cells.
Edit

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

GetNews 14 Mar 2025
Unlike traditional NK cells that may be neutralized when used alongside monoclonal antibodies (mAbs), GEAR-NK cells are engineered to resist antibody-based depletion ... cell-based cancer immunotherapies.
Edit

Myasthenia Gravis Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA ...

GetNews 14 Mar 2025
NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced the initiation of enrollment for the Ntrust-2 trial and the IND clearance for an investigator-sponsored trial (IST) of NKX019.
Edit

Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, ...

GetNews 12 Mar 2025
It attracts natural killer (NK) cells to induce rapid and near-complete depletion of blood and tissue eosinophils in most patients via apoptosis (programmed cell death).
Edit

ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025

Pharmiweb 10 Mar 2025
Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs) ... the effects of IL-15 super-agonist N-803 with ART in acute infection on T and NK cells.
Edit

Vulvar Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 06 Mar 2025
Preclinical studies have demonstrated that GI-101 exhibits strong anti-tumor efficacy, stimulating the proliferation of CD8+ T cells and natural killer (NK) cells while minimizing the expansion of ...
Edit

Nk Cell Therapy Pipeline 2024: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by ...

GetNews 05 Mar 2025
... Cell Therapy Market ... However, short life span, cumbersome preparation method of CAR NK cells, difficulties with NK cells and other factors are creating obstacles in the Nk Cell Therapy Market growth.
Edit

B-Cell Non-Hodgkin Lymphoma Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | ...

GetNews 05 Mar 2025
IBRX), a leader in immunotherapy, announced that the first patients have been dosed in an initial trial evaluating its CAR-NK cell therapy targeting CD-19 for non-Hodgkin’s lymphoma (NHL) ... B-Cell Non-Hodgkin Lymphoma Overview.
×